Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
446
Drug Approvals
Sertraline Hydrochloride Tablets
- Product Name
- 盐酸舍曲林片
- Approval Number
- 国药准字HJ20230148
- Approval Date
- Dec 29, 2023
Sevelamer Carbonate Tablets
- Product Name
- 碳酸司维拉姆片
- Approval Number
- 国药准字HJ20230122
- Approval Date
- Dec 29, 2023
Fampridine Sustained-release Tablets
- Product Name
- 氨吡啶缓释片
- Approval Number
- 国药准字HJ20230141
- Approval Date
- Dec 5, 2023
Valganciclovir Hydrochloride Tablets
- Product Name
- 盐酸缬更昔洛韦片
- Approval Number
- 国药准字HJ20230121
- Approval Date
- Oct 24, 2023
Olmesartan Medoxomil and Amlodipine Besylate Tablets
- Product Name
- 奥美沙坦酯氨氯地平片
- Approval Number
- 国药准字HJ20230099
- Approval Date
- Aug 8, 2023
Olmesartan Medoxomil and Amlodipine Besylate Tablets
- Product Name
- 奥美沙坦酯氨氯地平片
- Approval Number
- 国药准字HJ20230100
- Approval Date
- Aug 8, 2023
Olmesartan Medoxomil and Amlodipine Besylate Tablets
- Product Name
- 奥美沙坦酯氨氯地平片
- Approval Number
- 国药准字HJ20230101
- Approval Date
- Aug 8, 2023
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
News
ViiV Healthcare Expands Generic License for Long-Acting HIV Treatment to 133 Countries
ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.
Aurobindo Pharma Secures Multiple FDA Approvals for Generic Drug Portfolio Expansion
Aurobindo Pharma Limited has received FDA approval for multiple generic drug formulations, including critical medications for cardiovascular, neurological, and gastrointestinal conditions.
Aurobindo Receives FDA Approval for Generic Cephalexin Tablets
Aurobindo Pharma has received FDA approval for its generic version of Eli Lilly's Keflet tablets, containing cephalexin in 250 mg and 500 mg dosages.
Generic Manufacturers Secure Licenses for Long-Acting HIV Prevention Drug Cabotegravir
The Medicines Patent Pool has signed sublicense agreements with Aurobindo, Cipla, and Viatris to manufacture generic versions of cabotegravir long-acting for HIV pre-exposure prophylaxis in 90 countries.